Clinical trials directive takes shape:
This article was originally published in Clinica
The proposed EU directive on human clinical trials for medicines, which could set a precedent for medical device trials, has moved one step forward. The Council of Ministers has accepted amendments made by the European Parliament that include: risk/benefit judgments should be made by ethics committees; special protection should be given to individuals unable to give informed consent; and the principal investigator should always be a medical practitioner. Proposed amendments covering compensation for adverse effects or death from trials were not accepted.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.